Coherus Oncology (CHRS) Research & Development (2013 - 2026)

Coherus Oncology has disclosed Research & Development across 14 years of filings, most recently posting $21.5 million for Q1 2026.

• Research & Development for Q1 2026 came in at $21.5 million, down 11.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $106.1 million (up 20.86% YoY), and the FY2025 annual result was $108.9 million, up 18.57% from the prior year.
• Research & Development came in at $21.5 million for Q1 2026 at Coherus Oncology, down from $31.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $82.9 million in Q1 2022 to a low of $20.6 million in Q2 2024.
• The 5-year median for Research & Development is $26.4 million (2023), against an average of $31.2 million.
• Across the five-year window, Research & Development jumped 621.02% in 2022 and tumbled 58.81% in 2023, its largest moves.
• Coherus Oncology's Research & Development stood at $29.0 million in 2022, then retreated by 9.14% to $26.4 million in 2023, then decreased by 21.27% to $20.8 million in 2024, then surged by 49.21% to $31.0 million in 2025, then sank by 30.45% to $21.5 million in 2026.
• The last three Research & Development figures came in at $21.5 million (Q1 2026), $31.0 million (Q4 2025), and $27.3 million (Q3 2025), per Business Quant data.